32
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Main Recommendations

          Patients with chronic atrophic gastritis or intestinal metaplasia (IM) are at risk for gastric adenocarcinoma. This underscores the importance of diagnosis and risk stratification for these patients. High definition endoscopy with chromoendoscopy (CE) is better than high definition white-light endoscopy alone for this purpose. Virtual CE can guide biopsies for staging atrophic and metaplastic changes and can target neoplastic lesions. Biopsies should be taken from at least two topographic sites (antrum and corpus) and labelled in two separate vials. For patients with mild to moderate atrophy restricted to the antrum there is no evidence to recommend surveillance. In patients with IM at a single location but with a family history of gastric cancer, incomplete IM, or persistent Helicobacter pylori gastritis, endoscopic surveillance with CE and guided biopsies may be considered in 3 years. Patients with advanced stages of atrophic gastritis should be followed up with a high quality endoscopy every 3 years. In patients with dysplasia, in the absence of an endoscopically defined lesion, immediate high quality endoscopic reassessment with CE is recommended. Patients with an endoscopically visible lesion harboring low or high grade dysplasia or carcinoma should undergo staging and treatment. H. pylori eradication heals nonatrophic chronic gastritis, may lead to regression of atrophic gastritis, and reduces the risk of gastric cancer in patients with these conditions, and it is recommended. H. pylori eradication is also recommended for patients with neoplasia after endoscopic therapy. In intermediate to high risk regions, identification and surveillance of patients with precancerous gastric conditions is cost-effective.

          Related collections

          Author and article information

          Journal
          Endoscopy
          Endoscopy
          Georg Thieme Verlag KG
          0013-726X
          1438-8812
          March 18 2019
          April 2019
          March 06 2019
          April 2019
          : 51
          : 04
          : 365-388
          Affiliations
          [1 ]Gastroenterology Department, Portuguese Oncology Institute of Porto, Portugal
          [2 ]Center for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, Porto, Portugal
          [3 ]Surgery and Physiology Department, Faculty of Medicine of the University of Porto, Porto, Portugal,
          [4 ]Department of Gastroenterology, Porto University Hospital Centre, Institute of Biomedical Sciences, University of Porto (ICBAS/UP), Portugal
          [5 ]Gastroenterology Department, Portuguese Oncology Institute of Coimbra, Portugal
          [6 ]Institute of Clinical and Preventive Medicine, University of Latvia, Digestive Diseases Center, GASTRO, Riga, Latvia
          [7 ]Department of Medicine, Surgery and Translational Medicine University Hospital Sant’Andrea, University Sapienza Roma, Rome, Italy
          [8 ]INSERM U1053, Université de Bordeaux and CHU Pellegrin, Laboratoire de Bacteriologie, Bordeaux, France
          [9 ]IMAD, Hepato-Gastroenterology and Digestive Oncology, CHU de Nantes, University of Nantes, France
          [10 ]Gedyt Endoscopy Center, Buenos Aires, Argentina
          [11 ]Institute of Molecular Pathology and Immunology at the University of Porto (Ipatimup), Porto, Portugal
          [12 ]Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal
          [13 ]Service d’Anatomie Pathologique, Hôpital Saint-Antoine, AP-HP, Faculté de Médecine Sorbonne Université, Paris, France
          [14 ]Pathology Department, Centro Hospitalar de São João and Faculty of Medicine, Porto, Portugal
          [15 ]Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, The Netherlands
          [16 ]Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
          Article
          10.1055/a-0859-1883
          30841008
          8ca5c5b5-f72a-4b65-93df-b8995d164ca0
          © 2019
          History

          Comments

          Comment on this article

          scite_
          0
          0
          0
          0
          Smart Citations
          0
          0
          0
          0
          Citing PublicationsSupportingMentioningContrasting
          View Citations

          See how this article has been cited at scite.ai

          scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

          Similar content187

          Cited by323